Menu Search
Equities

Kindstar Globalgene Technology Inc

9960:HKG.HS

Kindstar Globalgene Technology Inc

Actions
  • Price (HKD)1.29
  • Today's Change-0.03 / -2.27%
  • Shares traded364.00k
  • 1 Year change-24.12%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kindstar Globalgene Technology Inc is a China-based investment holding company principally engaged in the provision of clinical testing services. The Company operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctors’ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.

  • Revenue in HKD (TTM)1.04bn
  • Net income in HKD44.57m
  • Incorporated2007
  • Employees3.13k
  • Location
    Kindstar Globalgene Technology IncEast Lake High Tech ZoneBiolake D2-1, 666 Gaoxin RoadWUHAN ChinaCHN
  • Websitehttps://www.kindstar.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.